Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use NGENLA safely and effectively. See full prescribing information for NGENLA. NGENLA (somatrogon-ghla) injection, for subcutaneous useInitial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
- generic_name
- somatrogon-ghla
- product_names
- somatrogon-ghla
- ndc
- 0069-0505, 0069-0520, 0069-0505-01, 0069-0505-02, 0069-0520-01, 0069-0520-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en